A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
Status:
Enrolling by invitation
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of treating patients with intermediate
risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and
lenalidomide (Rd) and patients with high risk SMM with combinational therapy with Rd and
carfilzomib.
Phase:
Phase 2
Details
Lead Sponsor:
Landspitali University Hospital
Collaborators:
Amgen Celgene Memorial Sloan Kettering Cancer Center University of Iceland